LRMR - Larimar Therapeutics Inc

Hold Momentum: Bearish

Recent News

This MicroStrategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Datadog ( NASDAQ:DDOG ) , Curbline Properties ( NYSE:CURB )

Benzinga • 7 months, 2 weeks ago • score: 0.30

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Morgan Stanley analyst Cesar Medina initiated coverage on Millicom International Cellular S.A.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, is focused on developing treatments for rare diseases. The company is headquartered in Bala Cynwyd, Pennsylvania.

52W High

$9.50

52W Low

$1.61

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.92

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-4.13

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

2.81

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

1.07%

Institutions (25–75% balanced)

83.77%

Shares Outstanding

85,590,000

Float

43,140,100

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-1.57

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.60%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.1172

0.1274

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025